File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis

TitlePerformance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis
Authors
KeywordsFamily history
Genetic risk score
High-penetrance genes
Prostate cancer
Risk assessment
Issue Date2021
Citation
European Urology, 2021, v. 79, n. 3, p. 419-426 How to Cite?
AbstractBackground: Single nucleotide polymorphism–based genetic risk score (GRS) has been developed and validated for prostate cancer (PCa) risk assessment. As GRS is population standardized, its value can be interpreted as a relative risk to the general population. Objective: To compare the performance of GRS with two guideline-recommended inherited risk measures, family history (FH) and rare pathogenic mutations (RPMs), for predicting PCa incidence and mortality. Design, setting, and participants: A prospective cohort was derived from the UK Biobank where 208 685 PCa diagnosis-free participants at recruitment were followed via the UK cancer and death registries. Outcome measurements and statistical analysis: Rate ratios (RRs) of PCa incidence and mortality for FH (positive vs negative), RPMs (carriers vs noncarriers), and GRS (top vs bottom quartile) were measured. Results and limitations: After a median follow-up of 9.67 yr, 6890 incident PCa cases (419 died of PCa) were identified. Each of the three measures was significantly associated with PCa incidence in univariate analyses; RR (95 % confidence interval [CI]) values were 1.88 (1.75–2.01) for FH, 2.89 (1.89–4.25) for RPMs, and 1.97(1.87–2.07) for GRS (all p < 0.001). The associations were independent in multivariable analyses. While FH and RPMs identified 11 % of men at higher PCa risk, addition of GRS identified an additional 22 % of men at higher PCa risk, and increases in C-statistic from 0.58 to 0.67 for differentiating incidence (p < 0.001) and from 0.65 to 0.71 for differentiating mortality (p = 0.002). Limitations were a small number of minority patients and short mortality follow-up. Conclusions: This population-based prospective study suggests that GRS complements two guideline-recommended inherited risk measures (FH and RPMs) for stratifying the risk of PCa incidence and mortality. Patient summary: In a large population-based prostate cancer (PCa) prospective study derived from UK Biobank, genetic risk score (GRS) complements two guideline-recommended inherited risk measures (family history and rare pathogenic mutations) in predicting PCa incidence and mortality. These results provide critical data for including GRS in PCa risk assessment. In this first population-based prospective cohort study, single nucleotide polymorphism–based genetic risk score (GRS) performs better than and complements two guideline-recommended inherited risk measures (family history and rare pathogenic mutations) in predicting prostate cancer (PCa) incidence and mortality. This provides critical data for including GRS in guidelines for PCa risk assessment.
Persistent Identifierhttp://hdl.handle.net/10722/314371
ISSN
2023 Impact Factor: 25.3
2023 SCImago Journal Rankings: 6.928
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorShi, Zhuqing-
dc.contributor.authorPlatz, Elizabeth A.-
dc.contributor.authorWei, Jun-
dc.contributor.authorNa, Rong-
dc.contributor.authorFantus, Richard J.-
dc.contributor.authorWang, Chi Hsiung-
dc.contributor.authorEggener, Scott E.-
dc.contributor.authorHulick, Peter J.-
dc.contributor.authorDuggan, David-
dc.contributor.authorZheng, S. Lilly-
dc.contributor.authorCooney, Kathleen A.-
dc.contributor.authorIsaacs, William B.-
dc.contributor.authorHelfand, Brian T.-
dc.contributor.authorXu, Jianfeng-
dc.date.accessioned2022-07-20T12:03:47Z-
dc.date.available2022-07-20T12:03:47Z-
dc.date.issued2021-
dc.identifier.citationEuropean Urology, 2021, v. 79, n. 3, p. 419-426-
dc.identifier.issn0302-2838-
dc.identifier.urihttp://hdl.handle.net/10722/314371-
dc.description.abstractBackground: Single nucleotide polymorphism–based genetic risk score (GRS) has been developed and validated for prostate cancer (PCa) risk assessment. As GRS is population standardized, its value can be interpreted as a relative risk to the general population. Objective: To compare the performance of GRS with two guideline-recommended inherited risk measures, family history (FH) and rare pathogenic mutations (RPMs), for predicting PCa incidence and mortality. Design, setting, and participants: A prospective cohort was derived from the UK Biobank where 208 685 PCa diagnosis-free participants at recruitment were followed via the UK cancer and death registries. Outcome measurements and statistical analysis: Rate ratios (RRs) of PCa incidence and mortality for FH (positive vs negative), RPMs (carriers vs noncarriers), and GRS (top vs bottom quartile) were measured. Results and limitations: After a median follow-up of 9.67 yr, 6890 incident PCa cases (419 died of PCa) were identified. Each of the three measures was significantly associated with PCa incidence in univariate analyses; RR (95 % confidence interval [CI]) values were 1.88 (1.75–2.01) for FH, 2.89 (1.89–4.25) for RPMs, and 1.97(1.87–2.07) for GRS (all p < 0.001). The associations were independent in multivariable analyses. While FH and RPMs identified 11 % of men at higher PCa risk, addition of GRS identified an additional 22 % of men at higher PCa risk, and increases in C-statistic from 0.58 to 0.67 for differentiating incidence (p < 0.001) and from 0.65 to 0.71 for differentiating mortality (p = 0.002). Limitations were a small number of minority patients and short mortality follow-up. Conclusions: This population-based prospective study suggests that GRS complements two guideline-recommended inherited risk measures (FH and RPMs) for stratifying the risk of PCa incidence and mortality. Patient summary: In a large population-based prostate cancer (PCa) prospective study derived from UK Biobank, genetic risk score (GRS) complements two guideline-recommended inherited risk measures (family history and rare pathogenic mutations) in predicting PCa incidence and mortality. These results provide critical data for including GRS in PCa risk assessment. In this first population-based prospective cohort study, single nucleotide polymorphism–based genetic risk score (GRS) performs better than and complements two guideline-recommended inherited risk measures (family history and rare pathogenic mutations) in predicting prostate cancer (PCa) incidence and mortality. This provides critical data for including GRS in guidelines for PCa risk assessment.-
dc.languageeng-
dc.relation.ispartofEuropean Urology-
dc.subjectFamily history-
dc.subjectGenetic risk score-
dc.subjectHigh-penetrance genes-
dc.subjectProstate cancer-
dc.subjectRisk assessment-
dc.titlePerformance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.eururo.2020.11.014-
dc.identifier.pmid33257031-
dc.identifier.scopuseid_2-s2.0-85097100144-
dc.identifier.volume79-
dc.identifier.issue3-
dc.identifier.spage419-
dc.identifier.epage426-
dc.identifier.eissn1873-7560-
dc.identifier.isiWOS:000694859600030-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats